Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.52 |
| ▸ | TDO2 | P48775 | 14/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138418 | 0.81 | IDO1 (0.54) | IDO1TDO2CYP2C9CYP3A4S1PR5 | |
| SCHEMBL3229223 | 0.80 | IDO1 (0.53) | IDO1TDO2CYP2C9CYP3A4S1PR5 | |
| SCHEMBL21138413 | 0.77 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP3A4 | |
| SCHEMBL3216524 | 0.72 | GAA (0.45) | IDO1TDO2CYP2C9CYP3A4 | |
| SCHEMBL21138838 | 0.71 | IDO1 (0.61) | IDO1TDO2CYP2C9CYP3A4S1PR5 | |
| SCHEMBL22635778 | 0.71 | IDO1 (0.45) | IDO1TDO2CYP2C9CYP3A4 | |
| SCHEMBL21430773 | 0.70 | IDO1 (0.52) | IDO1TDO2CYP2C9CYP3A4 | |
| SCHEMBL21138415 | 0.69 | IDO1 (0.47) | IDO1TDO2CYP2C9CYP3A4S1PR5 | |
| SCHEMBL21061068 | 0.68 | IDO1 (0.66) | IDO1TDO2CYP2C9CYP3A4S1PR5 | |
| SCHEMBL21408574 | 0.68 | IDO1 (0.52) | IDO1TDO2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TDO2 7/4885CYP2C9 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.